Check for updates

RESEARCH ARTICLE

REVISED Secretomes of apoptotic mononuclear cells ameliorate neurological damage in rats with focal ischemia [version 2; peer review: 1 approved, 2 approved with reservations]

Patrick Altmann^{1,2}, Michael Mildner³, Thomas Haider^{1,2}, Denise Traxler^{1,2}, Lucian Beer¹, Robin Ristl⁴, Bahar Golabi³, Christian Gabriel⁵, Fritz Leutmezer⁶, Hendrik Jan Ankersmit^{1,2}

¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, 1090, Austria

²Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration, Vienna, 1090, Austria

³Department of Dermatology, Medical University of Vienna, Vienna, 1090, Austria

⁴Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, 1090, Austria

⁵Red Cross Transfusion Service for Upper Austria, Linz, 4017, Austria

⁶Department of Neurology, Medical University of Vienna, Vienna, 1090, Austria

v2 First published: 19 Jun 2014, 3:131
<https://doi.org/10.12688/f1000research.4219.1>

Latest published: 28 Oct 2014, 3:131
<https://doi.org/10.12688/f1000research.4219.2>

Abstract

The pursuit of targeting multiple pathways in the ischemic cascade of cerebral stroke is a promising treatment option. We examined the regenerative potential of conditioned medium derived from rat and human apoptotic mononuclear cells (MNC), rMNC^{apo sec} and hMNC^{apo sec}, in experimental stroke.

We performed middle cerebral artery occlusion on Wistar rats and administered apoptotic MNC-secretomes intraperitoneally in two experimental settings. Ischemic lesion volumes were determined 48 hours after cerebral ischemia. Neurological evaluations were performed after 6, 24 and 48 hours. Immunoblots were conducted to analyze neuroprotective signal-transduction in human primary glia cells and neurons. Neuronal sprouting assays were performed and neurotrophic factors in both hMNC^{apo sec} and rat plasma were quantified using ELISA.

Administration of rat as well as human apoptotic MNC-secretomes significantly reduced ischemic lesion volumes by 36% and 37%, respectively. Neurological examinations revealed improvement after stroke in both treatment groups. Co-incubation of human astrocytes, Schwann cells and neurons with hMNC^{apo sec} resulted in activation of several signaling cascades associated with the regulation of cytoprotective gene products and enhanced neuronal sprouting *in vitro*. Analysis of neurotrophic factors in hMNC^{apo sec} and rat plasma revealed high levels of brain derived neurotrophic factor (BDNF). Our data indicate that apoptotic MNC-secretomes elicit

Open Peer Review

Approval Status ? ✓ ?

	1	2	3
version 2			
(revision)	?	✓	
28 Oct 2014	view	view	
	↑	↑	
version 1	?	?	?
19 Jun 2014	view	view	view

1. **Johannes Boltze**, Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany
2. **Michael Chopp**, Henry Ford Hospital, Detroit, USA
Hongqi Xin, Henry Ford Hospital, Detroit, USA
3. **An Zhou**, Morehouse School of Medicine, Atlanta, GA, USA

Any reports and responses or comments on the

neuroprotective effects on rats that have undergone ischemic stroke.

.....
article can be found at the end of the article.

Corresponding author: Hendrik Jan Ankersmit (hendrik.ankersmit@meduniwien.ac.at)

Competing interests: The Medical University of Vienna has claimed financial interest (Patent number: PCT/EP09/67534, filed 18 Dec 2008; Patent name: Pharmaceutical preparation comprising supernatant of blood mononuclear cell). Hendrik Jan Ankersmit is a shareholder of APOSCIENCE AG, which owns the rights to commercialize apoptotic MNC-secretomes for therapeutic use. All other authors declare that they have no competing interests. APOSCIENCE AG is a funder of his study.

Grant information: This study was funded by the Christian Doppler Laboratory for cardiac and thoracic diagnosis and regeneration.

Copyright: © 2014 Altmann P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original data is properly cited.

How to cite this article: Altmann P, Mildner M, Haider T *et al.* **Secretomes of apoptotic mononuclear cells ameliorate neurological damage in rats with focal ischemia [version 2; peer review: 1 approved, 2 approved with reservations]** F1000Research 2014, 3:131 <https://doi.org/10.12688/f1000research.4219.2>

First published: 19 Jun 2014, 3:131 <https://doi.org/10.12688/f1000research.4219.1>

REVISED Amendments from Version 1

We want to thank the invited referees for their valuable comments and suggestions. We feel that the scientific value of our manuscript has increased significantly. This revised version of the manuscript includes the following major adjustments as suggested by the referees:

We performed an additional experiment aiming at further characterizing the state of apoptosis in apoptotic MNC-secretomes. We found that about 85% of rMNC that had been irradiated and cultured for 18 hours are in the state of apoptosis (see Figure 3).

Other revised points include:

- The rationale for the two setting-approach plus the limitations of this study have been added to the Discussion.
- Behavioral data are now presented as mean $\pm$ SD (see Figure 5).
- Figure 8 now shows all ELISA data on neurotrophic factors in hMNC^{apo sec} *in vitro* + *in vivo*.
- Randomization processes for the animal study have been described in greater detail.
- Materials and Methods have been described more accurately as suggested (neuronal sprouting assay, production of MNC-secretomes, determination of neurotrophic factors, etc.).
- References for the production of apoptotic MNC-secretomes have been added.
- Orthographic errors and typos have been corrected.
- Ample commas in decimal numbers have been replaced by periods.

See referee reports

Introduction

The search for clinically effective strategies to intercept the deleterious events that follow a stroke is ongoing. This quest has been particularly driven by the limitations that the use of tissue plasminogen activator (tPA) poses in patients with ischemic stroke (Fonarow *et al.*, 2011). For Europe, it is projected that stroke events will increase from 20% in 2002 to 35% in 2050 in the population above 65 years of age (Truelsen *et al.*, 2006). The United States report a yearly incidence of approximately 795,000, killing about 135,000 people each year (Roger *et al.*, 2012). Most patients have to settle for the need of specialized care culminating into a burden to both persons affected and health care systems (Strong *et al.*, 2007). Even though the potential of targeting neuroprotective pathways to treat ischemic stroke has been debated extensively, there seems to be a consensus towards more multilayered strategies (Iadecola & Anrather, 2011).

Several neuroprotective proteins that play a role in the ischemic cascade have been identified and studied, such as cAMP response element-binding protein (CREB), Akt, extracellular-signal regulated kinase (Erk1/2), or heat shock protein 27 (HSP27) (Qi *et al.*, 2012; Roux & Blenis, 2004). The transcription factor CREB, for instance, exerts its neuroprotective role in the ischemic response by activating protective genes and trophic factors such as B-cell lymphoma 2 (Bcl-2) or brain-derived neurotrophic factor (BDNF) (Wilson *et al.*, 1996). The protein-chaperone HSP27 inhibits pathways leading to

cell death (van der Weerd *et al.*, 2010). Finding a treatment targeting these proteins simultaneously could open a new window of opportunity in acute stroke management and regeneration.

The role of different populations of adult stem cells is being investigated in several fields of regenerative medicine. Distant stem cells track sites of injury and counteract tissue damage (Assmus *et al.*, 2011; Brunner *et al.*, 2008; Lagasse *et al.*, 2000). It is hypothesized that human mesenchymal stem cells (hMSCs) produce cytokines and growth factors that subsequently repair damaged tissues, including the brain (Chen *et al.*, 2001). After homing to the injured areas, where hypoxia, apoptosis, and inflammation occur, hMSCs secrete trophic factors that enable endogenous repair (Joyce *et al.*, 2010). Hence, the scientific community endeavored to either infuse or inject stem cells in multiple organ-specific disease entities with only limited clinical success in myocardial infarction (Jensen & Patterson, 2013; Lemmens & Steinberg, 2013; Wollert & Drexler, 2010).

In 2005, Thum *et al.* postulated in their “dying stem cell hypothesis” that therapeutic stem cells are already in the state of apoptosis while being processed for treatment, thus causing immune suppression by scaling down the adaptive and innate immune system (Thum *et al.*, 2005). The authors speculated that these “therapeutic apoptotic stem cells” are able to attenuate hypoxia-induced inflammation (Fadok *et al.*, 2001; Saas *et al.*, 2010).

We have extended this concept and utilized suspensions of apoptotic peripheral blood mononuclear cells (MNCs), rather than stem cells themselves, as a therapeutic agent for the treatment of rodent myocardial infarction in a previous study (Ankersmit *et al.*, 2009; Hoetzenecker *et al.*, 2012; Lichtenauer *et al.*, 2011). The almost complete absence of long term myocardial scarring led us to newly validate the suitability of peripheral MNCs and their secreted factors for regenerative medicine. In our previous work we showed that first, human apoptotic MNC-secretomes (hMNC^{apo sec}) circumvented inflammation and caused preferential homing of c-kit+/CD34- endothelial progenitor cells; second, hMNC^{apo sec} caused immune suppression *in vitro* and, third, paracrine factors derived from human apoptotic MNC-secretomes led to an upregulation of matrix metalloproteinase 9 (MMP-9) and Interleukin 8 (IL-8) in primary cultured human fibroblasts. Both these factors are known to be involved in neoangiogenesis (Nold-Petry *et al.*, 2010). In addition, hMNC^{apo sec} have been shown to cause enhanced wound healing *in vivo* via the formation of new blood vessels and increased migration of primary cultured fibroblasts and keratinocytes (Mildner *et al.*, 2013). Ultimately, one single intravenous administration of hMNC^{apo sec} in a large animal closed chest reperfusion model of acute myocardial infarction (AMI) prevented myocardial damage (Ankersmit *et al.*, 2009; Hoetzenecker *et al.*, 2012; Lichtenauer *et al.*, 2011).

With these data at hand, we investigated in the present study whether secretomes derived from rat (rMNC^{apo sec}) and human (hMNC^{apo sec}) apoptotic MNCs are also able to reduce ischemic lesion volumes and improve neurological outcome in a rat MCAO (middle cerebral artery occlusion) model.

Materials and methods

Ethics statement

All animal procedures were approved by the Animal Research Committee of the Medical University of Vienna (Protocol No.: 66.009/127-II/3b/2011) in accordance to the guidelines for the Care and Use of Laboratory Animals by the National Institutes of Health. Efforts were made to minimize suffering.

For the production of human MNC-secretomes, human MNCs were isolated from whole blood of healthy volunteers. This was approved by the ethics committee of the Medical University of Vienna (approval number: EK 2010/034). Participants provided their written informed consent.

Animals

A total of 84 adult male Wistar Rats (Charles River Laboratories, Sulzfeld, Germany) weighing 280–320 g were used. Animals were kept in cages of three to four and accustomed to a 12 hour light-dark cycle for two weeks. Nutrition and tap water were provided ad libitum. Sixteen animals made up the secretome group for which MNCs were extracted out of whole blood and their secretomes produced. Ten animals were randomly selected for the pilot-phase with the intention of establishing protocol and attaining a consistent surgical technique. The remaining 58 animals were used for the study groups and randomly assigned to either the control or the treatment group. Deaths occurred equally in both study groups (total N=21, n=10 in setting 1 [rMNC^{apo sec}] and n=11 in setting 2 [hMNC^{apo sec}], 7 animals were excluded from the study (n=3 in setting 1 and n=4 in setting 2) and euthanized within 6 hours after MCAO due to severe dyspnea and suffering. For statistical analyses, the remaining 30 animals were used (n=16 in setting 1 and n=14 in setting 2). Data were analyzed in a blinded manner. Animals' tails were marked with colored ink pens before surgery. From that moment on, investigators registered values using only that color code. Surgery was performed by a surgeon unaware if the animals received treatment or placebo. Neuroscore was evaluated by an investigator not involved in the surgical procedure or application of compounds. Statistical analyses were performed by an external statistician.

Production of apoptotic MNC-secretomes from rats (rMNC^{apo sec}) and control medium for experimental setting 1

This section describes the production of apoptotic MNC-secretomes derived from rats (Hoetzenecker *et al.*, 2013). These were used for the treatment group in setting 1 whereas the treatment group in setting 2 received apoptotic MNC-secretomes derived from humans (see below). Syngeneic rat-MNCs were harvested from splenocytes of Wistar rats. For this procedure, animals were anesthetized with an intraperitoneal administration of Ketamine (100 mg/kg) and Xylazine (10 mg/kg). Through a midline incision, spleens were harvested and MNCs were separated by passing spleens through 70 µm and 40 µm cell strainers (BD Biosciences, Vienna, Austria). Red blood cells were lysed for 90 seconds using a red blood cell lysing buffer (Sigma Aldrich, Vienna, Austria). After washing, MNCs were resuspended in 4 mL CellGro serum-free medium (CellGenix GmbH, Freiburg, Germany) and apoptosis was induced by Caesium-137 irradiation (Department of Transfusion Medicine, Vienna General Hospital) with 45 Gy. Cells were cultivated in CellGro serum-free medium at a concentration of 25×10⁶ cells/mL at 37°C

and 5% CO₂ for 18 hours. Cells were removed by centrifugation at 1300 RPM for 9 minutes (Beckman Coulter Allegra® X-15R, Brea, CA, USA) and cell culture supernatants were then dialyzed against 50 mM ammonium acetate (Sigma Aldrich) using dialysis membranes (cut off: 6–8 kDa; Spectrum laboratories, Breda, The Netherlands) for 24 hours at 4°C on a shaking platter. Subsequently, the dialyzed supernatants were lyophilized over night (Lyophilizator Christ alpha 1–4, Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz, Germany). Lyophilization was performed at -20°C and 0.1 mbar pressure. The final product, rMNC^{apo sec}, was stored at -80°C. For the control group, the same cell culture medium that was used for the production of rMNC^{apo sec} was irradiated, cultivated, dialyzed, and lyophilized accordingly. All cell and tissue samples were handled under sterile conditions. Microbial smears on chocolate agars (BD Biosciences, Vienna, Austria), a non-selective media for cultivation of fastidious microorganisms, were performed before lyophilization to rule out contaminations.

Production of apoptotic MNC-secretomes from humans (hMNC^{apo sec}) and control medium according to GMP protocol for experimental setting 2

Pathogen-reduction methods such as photodynamic treatment with methylene blue (MB) plus visible light and gamma radiation have been developed to inactivate viruses and other pathogens in plasma and platelet concentrates. Regulatory authorities require these two pathogen reduction steps for blood derived products such as IVIg, plasma or coagulation factors (Gauvin & Nims, 2010; Lambrecht *et al.*, 1991; Nims *et al.*, 2011; Wallis & Melnick, 1965) to be performed in a good manufacturing practice (GMP) facility.

Human apoptotic MNC-secretomes were prepared as described previously (Lichtenauer *et al.*, 2011). Briefly, venous blood samples (75 mL) were drawn from healthy volunteers (n=15). Blood cells were separated using Ficoll-Paque (GE Healthcare Bio-Sciences AB, Stockholm, Sweden) density gradient centrifugation. MNCs were resuspended with CellGro serum-free medium. After irradiation with 45 Gy as described above, cells were cultivated with CellGro serum-free medium at a concentration of 25×10⁶ cells/mL under sterile conditions for 18 hours. Supernatants were collected by centrifugation and methylene blue (MB) plus light treatment was performed in the Theraflex MB-Plasma system (MacoPharma, Mouvax, France) using the Theraflex MB-Plasma bag system (REF SDV 0001XQ) and an LED-based illumination device (MacoTronic B2, MacoPharma). Light energy was monitored and reached 120 J/cm². Integrated in the bag system was a pill containing 85 mg of MB, yielding a concentration range of 0.8 to 1.2 mM MB per unit. Removal of MB and photoproducts by Blueflex filtration was done consecutively after treatment. Air was removed from the plasma units before illumination. After lyophilization of this viral inactivated cell culture supernatant as indicated above, the lyophilized powder ran through the second step of pathogen removal, gamma irradiation. Gamma irradiation was performed by Mediscan, which operates a gamma irradiation unit (Gammatron 1500, Mediscan, Seibersdorf, Austria). Gamma rays were generated by radioactive decay of Cobalt 60. For this purpose, apoptotic MNC-secretomes were put in metal sterilization totes that pass on a meandering path through the irradiation vault around the emitting center in five layers. The cobalt unit emits photons that are almost

isotropic. Regarding the complex path (280 positions in five layers) the dose is distributed consistently. The dose rate recorded by a Polymethyl methacrylate (PMMA) dosimeter was determined to be 25000 Gy after 23 hours of irradiation. The lyophilized and two-step pathogen-free supernatant of apoptotic MNCs (hMNC^{apo sec}) was stored at -80°C. For the control group, cell culture medium was put through the same steps (cultivation, two step pathogen reduction, irradiation and lyophilization).

Verification of apoptosis in cultured irradiated apoptotic rMNCs using flow cytometry

Syngeneic rMNCs (MNCs derived from rats) were harvested from splenocytes of Wistar rats (n=5) using the same protocol as described earlier. To investigate apoptosis rates during the production of our compounds, washed MNCs that had been cultured for 18 hours were divided into two groups, one to be irradiated in order to induce apoptosis (as described before by using Caesium-137 irradiation with 45 Gy) the other to remain non-irradiated. Except for irradiation, MNCs in both groups were processed equivalently (cultivation, dialysis, lyophilization). Co-staining with Annexin-V/Propidium Iodide (FITC/PI, Becton Dickinson, Franklin Lakes, NJ, USA) was performed following manufacturer's instructions. The rate of apoptosis was then evaluated on a flow cytometer (FC500, Coulter, CA, USA).

Animal preparation and induction of focal cerebral ischemia

Fifty eight animals were weighed and anesthetized with an intraperitoneal administration of Ketamine (100 mg/kg) and Xylazine (10 mg/kg). This was followed by a subcutaneous injection of Piritramide (15 mg/kg). Animals were then intubated with an 18G intravenous catheter (BD Biosciences) and anesthesia was maintained throughout surgery with 1.5% isoflurane delivered in 1.5 L air and 0.8 L oxygen per minute. Body temperature was regulated using a heating pad (Trixie 76085 Heizmatte, Trixie, Flensburg, Germany). Permanent middle cerebral artery occlusion (MCAO) of the right hemisphere was performed according to the suture model described

by Zea Longa *et al.* using a coated monofilament (Doccol Corporation, CA, USA) (Longa *et al.*, 1989). Briefly, a 3 cm coated monofilament with a thickened tip was inserted into the external carotid artery (ECA) and advanced to the middle cerebral artery (MCA) to induce ischemia in the MCA territory.

Postoperative administration of apoptotic MNC-secretomes

In the first experimental setting, lyophilized rMNC^{apo sec} (produced from 12.5×10^6 apoptotic rat MNCs) or control medium was resuspended in 0.3 mL saline (Fresenius Kabi, Vienna, Austria) in the laboratory prior to surgery. In order to investigate the potency of apoptotic MNC-secretomes, both the treatment group and the control group (n=29) randomly received 0.3 mL rMNC^{apo sec} or control medium intraperitoneally forty minutes after surgery (Figure 1, blue arrow). In the second setting, lyophilized hMNC^{apo sec} (produced from 12.5×10^6 apoptotic human MNCs) or lyophilized control medium were each resuspended in the laboratory in 0.3 mL saline prior to surgery. In order to investigate whether a higher dosage and time interval would provide additional benefits, animals from experimental setting 2 (n=29) received two intraperitoneal doses 40 minutes and 24 hours after MCAO induction (Figure 1, red arrows). The rationale for this two-step-approach is given in the discussion. In addition, all animals were given a subcutaneous injection of 3.5 mL/kg saline after surgery and put under a heating lamp until they woke up.

Measurement of infarct volumes

In both experimental settings, animals were euthanized 48 hours after surgery with an intraperitoneal injection of 600 mg/kg Pentobarbital. Brains were harvested and cut into five 2 mm coronal slices using a brain matrix (Zivic Instruments, Pittsburgh, PA, USA) and razor blades (Zivic Instruments). In order to stain ischemic areas, brain slices were then incubated for 30 minutes at 37°C in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC; Carl Roth, Karlsruhe, Germany) (Bederson *et al.*, 1986). Slices were digitalized

Figure 1. Experimental study setting. For setting 1, rMNC^{apo sec} (apoptotic MNC-secretomes from rats) were injected 40 minutes after MCAO (blue arrow). In setting 2, hMNC^{apo sec} (apoptotic MNC-secretomes from humans) were administered twice at 40 minutes (0.7 hours) and 24 hours after MCAO (red arrows). In both settings, neurological evaluations were performed at 0 hours (before surgery) as well as 6, 24, and 48 hours after surgery (boxes). Both treatment and control animals were euthanized 48 hours after surgery and brain slices were treated with TTC (2,3,5-triphenyltetrazolium chloride) to stain ischemic areas in the brain.

using a commercially available photo scanner (Epson Perfection V330 Scanner; [Figure 2](#)). Lesion volumes were determined by a blinded investigator using ImageJ planimetry software (Version 1.6.0_10; Rasband, W.S., ImageJ, U.S. National Institutes of Health; Bethesda, MD, USA). Lesion volumes were calculated with respect to edema formation using the following formula: $100 \times (\text{Volume of the contralateral hemisphere} - \text{Volume of the ipsilateral hemisphere}) / (\text{Volume of the contralateral hemisphere})$. Ipsi- and contralateral lesion volumes were calculated by multiplication of area with slice thickness summed for all sections ([Swanson et al., 1990](#)).

Figure 2. Representative brain slices of rats subjected to MCAO. Brains were stained with a 2% solution of TTC forty-eight hours after MCAO. Animals received either treatment (in this representative scan: hMNC^{apo sec}) or control medium, in this case, 40 minutes 24 hours after surgery. White areas indicate ischemic tissue while red areas stain for non-ischemic tissue. Animals treated with control medium (left image) had larger ischemic (=white) areas than animals treated with hMNC^{apo sec} (right image).

Neurological evaluation

Neurological examinations were performed by a blinded investigator in both experimental settings using a neurological score before surgery, and 6, 24, and 48 hours after surgery. The test at each time point consists of seven exercises and animals would receive a score ranging from 0 points (no pathological responses) to 7 points (maximum impairment). A successfully completed exercise would add 0 points to the score. Pathological performance in an exercise would add 1 point. The exercises were: left forepaw extension, instability to lateral push from right, tail hanging, walking on ground, whisker movement on the left, hearing, and vision ([Nedelman et al., 2007](#)). E.g. if the rats could not hold against a hand pushing them from the right, they would get 1 point. If they did push against the examiner's hand, they would get 0 points. Accordingly, if the rats did extend their left forepaw when hauled up by their tail, they would get 0 points. If they could not extend their left forepaw, they would get 1 point. This adds up to a score ranging from 0 points (=no pathological response at all), to 7 points (=highly impaired animal).

Cell culture

Human primary astrocytes, Schwann cells and neurons were obtained from CellSystems (CellSystems Biotechnologie, St. Katharinen, Germany) and cultured in their respective growth medium (CellSystems) at 37°C and 5% CO₂.

Western blot analysis

3×10⁶ astrocytes, Schwann cells and 3×10⁵ neurons were seeded in 6-well plates (Costar, Vienna, Austria) and cultured overnight in their respective growth medium. After removal of the medium, cells were washed twice at room temperature with PBS (Gibco BRL, Gaithersburg, MA, USA) and cultured in their respective basal medium (Astrocyte or Schwann cell growth medium (CellSystems) without growth supplements) for 3 hours. Aliquots of lyophilized human MNC-secretome and control medium were resolved in the different basal media at a 10-fold concentration (lyophilized secretome, derived from 25×10⁶ cells/mL). One tenth of this solution was then directly added to the cell cultures. After 1 hour, the cells were washed at room temperature with PBS and lysed in 200 µL SDS-PAGE loading buffer (100 mL contain: 1g SDS (Sigma, Vienna, Austria), 3 mg EDTA (Sigma) and 0.75g TRIS (Sigma). pH is adjusted with HCl (Merck, Vienna, Austria) to 6.8 for 10 minutes at room temperature. After sonication (Laborpartner, Vienna, Austria: output = 100%; 20 Cycle for 1 second each) and centrifugation (20000g for 10 minutes) proteins were size-fractionated by SDS-PAGE through an 8 to 18% gradient gel (Amersham Pharmacia Biotech, Uppsala, Sweden) and transferred to nitrocellulose membranes (BioRad, Hercules, CA, USA). Immunodetection was performed with anti-c-Jun (Cell Signaling Technology, Inc. Danvers, MA, USA; 1µg/mL, #9165), anti-phospho-c-Jun (Cell Signaling Technology; 1µg/mL, #9261), anti-CREB (Cell Signaling Technology; 1µg/mL, #9197), anti-phospho-CREB (Cell Signaling Technology; 1µg/mL, #9198), anti-Akt (Cell Signaling Technology; 1µg/mL, #2938), anti-phospho-AKT (Cell Signaling Technology; 1µg/mL, #9271), anti-Erk1/2 (Cell Signaling Technology; 1µg/mL, #4695), anti-phospho-Erk1/2 (Cell Signaling Technology; 1µg/mL, #4376), anti-HSP27 (Cell Signaling Technology; 1µg/mL, #2402), anti-phospho-Hsp27 (Cell Signaling Technology; 1µg/mL, #2404) followed by an HRP-conjugated goat anti-mouse IgG antiserum or a goat anti-rabbit IgG antiserum (GE Healthcare, Freiburg, Germany). Reaction products were detected by chemiluminescence with the ChemiGlow reagent (Biozyme Laboratories Limited, South Wales, U.K.) according to the manufacturer's instructions.

Neuronal sprouting assay

To investigate neuronal sprouting of human primary neurons, 1×10⁴ cells (CellSystems) were seeded in 24-well plates (Costar) and allowed to adhere for 24 hours. Cells were further cultivated in neuronal medium (see above) without growth factors for five days together with the secretome of hMNC derived from 2.5×10⁶ cells/mL (hMNC^{apo sec}) or control medium. After five days cells were fixed at room temperature in 100% methanol for 10 minutes and stained with methylene blue (Sigma; 0.5% in methanol). Excess methylene blue was washed out with distilled water, and culture wells were evaluated with an inverted microscope (EvoXL, Life Technologies, Carlsbad, CA, USA). Cell cultures were digitalized using an Olympus Digital Camera E-520 (3648×2736 pixels). A blinded observer set a random representative area of the photographed cell

culture (as seen in [Figure 7b](#)) using Adobe Photoshop Lightroom Software (Version 5.2, 2013; Adobe, San José, CA, USA). (i) on a photograph of cells treated with human apoptotic MNC-secretomes and (ii) on a photograph showing cells treated with control medium. The areas in each photograph measured 1420×2456 pixels. Subsequently, they picked and marked visible distinct, full-length and non-overlapping 30–35 neurites using ImageJ software (Bethesda, MD). Another blinded investigator measured these marked neurons using ImageJ software.

Determination of neurotrophic factors in apoptotic MNC-secretomes and control medium

BDNF, nerve growth factor (NGF) and glial derived neurotrophic factor (GDNF) in rMNC^{apo sec}, hMNC^{apo sec}, and control medium, were measured using commercially available ELISA-kits (Enzyme linked immunosorbent assay; BDNF: catalog# DY248; beta-NGF catalog# DY256; GDNF catalog# DY212; R&D Systems, Minneapolis, MN, USA). All samples were assayed in triplicates. Manufacturer's instructions were followed and plates were read at 450 nm on a Wallac Multilabel counter 1420 (PerkinElmer, Boston, MA, USA).

Determination of BDNF in rat plasma

To see whether intraperitoneal administration of apoptotic MNC-secretomes and control medium influence BDNF production, six rats were injected intraperitoneally with hMNC^{apo sec} (n=3), or control medium, (n=3). Rats were euthanized with an intraperitoneal injection of 600 mg/kg Pentobarbital 24 hours after injection with hMNC^{apo sec} (secretomes of 12.5×10^6 cells) or control medium. Blood was retrieved in heparinized tubes, centrifuged, and plasma was stored at -20°C. Rat BDNF levels were measured using a commercially available BDNF-ELISA (catalog# KA0330, Abnova, Taipei, Taiwan) and plates were read at 450 nm on a Wallac Multilabel counter 1420 (PerkinElmer, Boston, MA, USA).

Statistical analyses

To test for differences in lesion volume between control and treatment groups the Mann-Whitney *U*-test was applied. Differences were also assessed graphically using box-plots. The calculations were performed separately for each experimental setting. Linear mixed models were calculated to explain neuroscores by time point, treatment and interaction effects between time point and treatment. A random intercept term was included for each individual animal to account for the correlation of observations within an individual. The calculations were done using the MIXED procedure in SAS 9.3. The neuroscores were also assessed graphically by plotting a time curve of mean neuroscore values±SD for each group. Neurite lengths in neuronal cultures were compared applying the student's *t*-test. A *p*-value of 0.05 or below was considered significant.

Results

Apoptosis rates in irradiated apoptotic rMNCs

In order to see the extent of apoptosis in rMNCs that had been cultured for 18 hours, we analyzed apoptosis rates in cultured irradiated and cultured non-irradiated rMNCs from 5 donors using flow cytometry. Analysis of cultured irradiated rMNCs revealed apoptosis rates of $85 \pm 5\%$ (mean±SD) while $12 \pm 5\%$ did not stain for FITC/PI, thus being viable. In the non-irradiated rMNC control group, $44 \pm 7\%$ cells were apoptotic with $55 \pm 7\%$ still being viable ([Figure 3](#)).

Apoptotic MNC-secretomes reduce the infarction volume in an experimental MCAO model

In a rat model of MCAO we examined the potential of apoptotic MNC-secretomes to reduce ischemic lesion volumes in an allogeneic (experimental setting 1, rMNC^{apo sec}) and a xenogeneic approach (experimental setting 2, hMNC^{apo sec}) ([Figure 1](#)). The results of the allogeneic setting displayed significantly lower lesion volumes in the treatment group compared to the control group as shown by TTC-staining ([Figure 4](#)). Treatment with rMNC^{apo sec} led to a mean decrease of 36% in total infarct volume. Hemispheric lesion volumes (mean±SD) in the control group were $59 \pm 8\%$ ranging from 50% to 73% (Mann Whitney *U*-test; * *p*=0.0006; [Figure 4a](#)). The treatment group had a mean hemispheric lesion volume of $38 \pm 11\%$ ranging from 24% to 51%. In the xenogeneic setting, we injected hMNC^{apo sec} 40 minutes and 24 hours after MCAO. The reduction of the infarction volume in the xenogeneic setting was statistically significant and comparable to that observed in the allogeneic setting (Mann Whitney *U*-test; * *p*=0.0041; [Figure 4b](#)). The mean decrease in total infarct volume was 37%. Hemispheric lesion volumes (mean±SD) in the control group were $52 \pm 8\%$ ranging from 42% to 67%. The treatment group had a mean hemispheric lesion volume of $33 \pm 11\%$ ranging from 21% to 48%.

Apoptotic MNC-secretomes improve neurological outcome in an experimental MCAO model

In order to discover the effects of apoptotic MNC-secretomes on the neurological outcome, we performed a neurological exam on each animal at 4 specific time points. The first score was measured prior to surgery (baseline; 0 hours) and was 0 points for all animals. This was followed by 3 postoperative measurements at 6, 24 and 48

Figure 3. Apoptosis rates in irradiated and non-irradiated cultured rMNCs. Mean percentage values of viable (white) and apoptotic (red) rMNCs are given in this bar graph. The percentage of cells in either state are shown for non-irradiated rMNCs (control) and irradiated rMNCs after 18 hours in cell culture. Irradiated rMNCs correspond to the compound we used throughout the study.

Figure 4. Infarct volumes in control animals and animals treated with apoptotic MNC-secretomes. The percentage of hemispheric lesion volumes (%HLV) are represented as box and whiskers plots, wherein the boxes indicate the 1st and the 2nd quartile and the whiskers the minimum and maximum within 1.5 times the interquartile range from the box. Figure 4a shows lesion volumes as the extend of ischemia in setting 1, where apoptotic MNC-secretomes derived from rats were administered 40 minutes after MCAO compared to controls. Figure 4b corresponds to setting 2, where apoptotic MNC-secretomes derived from humans were administered 40 minutes and 24 hours after MCAO. In both settings, MNC^{apo sec} (red boxes) caused a significant decrease in infarct volumes (* $p=0.0006$ for setting 1, Figure 4a, and * $p=0.0041$ for setting 2, Figure 4b) compared to the control group (white boxes) that received only cell culture medium.

hours. All animals expressed neurological stroke-symptoms immediately after anesthesia wore off. The fixed effect coefficient estimates of the mixed models, their standard errors and p -values are shown in Table 1a and Table 1b. The factor Treatment was coded in a way that Treatment=0 corresponds to the control group and Treatment=1 corresponds to the treatment group. The time point 6 h is the reference group for the factor Time.

The results from both settings are similar. At time point 6 h there is no significant mean difference in the neuroscores between control and treatment, which is suggested by the coefficient for Treatment. The coefficients for Time 24 h and Time 48 h are not significantly different from zero. We can therefore not conclude that the mean neuroscore in the control group changes with time. The interaction terms for Treatment and Time, however, are significant. This indicates a significant decrease in the mean neuroscore over time in the treatment group. These results correspond well to the graphical depictions of the time curves (Figures 5a and 5b).

Apoptotic MNC-secretomes activate signaling cascades involved in cytoprotection in glia cells
Glia cells are non-neuronal cells that provide support and protection for neurons in the brain and peripheral nervous system (Giaume *et al.*, 2010). We therefore investigated the potency of hMNC^{apo sec}

Table 1. Fixed effect coefficient estimates of the mixed models and their standard errors. Data include both experimental setting 1 that used apoptotic MNC-secretomes derived from rats, "rMNC^{apo sec}", (Table 1a), and setting 2 that used apoptotic MNC-secretomes derived from humans, "hMNC^{apo sec}", (Table 1b). p -values are calculated from t-tests with the null hypothesis of the true coefficient being equal to 0. The factor Treatment was coded in a way that Treatment=0 corresponds to the control group and Treatment=1 corresponds to the treatment group. The time point 6 h is the reference group for the factor Time.

Table 1a: Linear mixed model analysis for setting 1. "rMNC ^{apo sec} ".			
Effect	Estimate	Standard Error	p
Intercept	5	0.2502	<.0001
Time 24 h	0	0.2566	1
Time 48 h	-0.1875	0.2566	0.471
Treatment	-0.0625	0.3538	0.8611
Treatment*Time 24 h	-1.0625	0.3629	0.0067
Treatment*Time 48 h	-1.5625	0.3629	0.0002

Table 1b: Linear mixed model analysis for setting 2. "hMNC ^{apo sec} ".			
Effect	Estimate	Standard Error	p
Intercept	4.5714	0.2761	<.0001
Time 24 h	0.1429	0.3442	0.6818
Time 48 h	-0.5	0.3442	0.1593
Treatment	0	0.3905	1
Treatment*Time 24 h	-1.4286	0.4868	0.0072
Treatment*Time 48 h	-1.6429	0.4868	0.0025

Figure 5. Neurological outcome score in control animals and animals treated with apoptotic MNC-secretomes. Mean neuroscores ($\pm$ SD) are plotted over time. Treated animals (red triangles for setting 1, Figure 5a, and red squares for setting 2, Figure 5b) improved over time compared to controls (black/white triangles for setting 1, Figure 5a, and black/white squares for setting 2, Figure 5b). Error bars correspond to $\pm$ one standard deviation.

to activate/phosphorylate signaling-molecules that are part of protective pathways in human primary astrocytes as well as in Schwann cells. For Western blot analysis, astrocytes and Schwann cells were treated with hMNC^{apo sec} for 1 hour. Both cell types showed an increased phosphorylation of CREB, Erk1/2, c-Jun, and Akt. Phosphorylation of HSP27 was only detected in astrocytes (Figure 6).

Apoptotic MNC-secretomes induce CREB phosphorylation and neuronal sprouting in human primary neurons and contain BDNF

We next investigated whether hMNC^{apo sec} are also effective in human primary neuron cultures. Western blot analysis of neurons and astrocytes revealed a rapid dose dependent activation of CREB phosphorylation (Figure 7a). Incubation of neurons with apoptotic MNC-secretomes led to a significant increase in the length of newly sprouting neurons. Cultured neurons treated with hMNC^{apo sec} had a mean neurite length of $21 \pm 1 \mu\text{m}$ (mean $\pm$ SEM) versus $13 \pm 1 \mu\text{m}$ in neurons treated with control medium (t-test; * $p < 0.0001$; Figure 7b-c).

In order to characterize the composition of neurotrophic factors present in hMNC^{apo sec}, we performed ELISA for BDNF, GDNF and NGF. Interestingly, only high amounts of BDNF ($356 \pm 14 \text{ pg/mL}$) were detected in hMNC^{apo sec}, suggesting an exclusive role for this neurotrophic factor in hMNC^{apo sec} (Figure 8a).

Effects of apoptotic MNC-secretomes on plasma BDNF-levels in rats

After revealing BDNF as one component in hMNC^{apo sec}, BDNF levels in plasma of rats treated with hMNC^{apo sec} were measured with ELISA 24 hours after i.p. administration. Plasma BDNF-levels were higher in rats treated with hMNC^{apo sec} compared to those treated with control medium ($n=3$ for each compound). Twenty four hours after treatment with hMNC^{apo sec}, BDNF plasma levels were $72 \pm 5 \text{ ng/mL}$ (mean $\pm$ SEM) compared to undetectably low BDNF levels in controls (Figure 8b).

Figure 6. Expression of cytoprotective proteins in human Astrocytes (AC) and Schwann Cells (SCs). Cell extracts were prepared after stimulation with hMNC^{apo sec} or cell culture Medium as control. Western blot analysis revealed an activation of CREB, ERK1/2, c-Jun, Akt, and HSP27. Proteins were normalized to the respective non-phosphorylated proteins.

Figure 7. Enhanced CREB phosphorylation and neurite length in neurons treated with apoptotic MNC-secretomes. (a) Cell extracts were prepared after stimulation with hMNC^{apo sec} or cell culture medium as control. Western blot analysis for phospho-CREB revealed a dose dependent activation of CREB in astrocytes and in neurons. (b) Neuron cultures treated with hMNC^{apo sec} or control medium for five days were stained with methylene-blue. One representative picture of ten is shown. Bar=10 μm (c) Lengths of neurons treated with hMNC^{apo sec} or cell culture medium as control were calculated using ImageJ software. Bars represent the mean of five different cultures.

Figure 8. Profile of neurotrophic factors in hMNC^{apo sec} and animals treated with hMNC^{apo sec}. (a) ELISA for BDNF, GDNF, and NGF detected only levels of BDNF (356±14pg/mL, mean±SEM) in hMNC^{apo sec}. (b) Six animals received an intraperitoneal injection with hMNC^{apo sec} (n=3, red bar) or control medium (n=3, black/white bar) and BDNF plasma levels were determined 24 hours after administration using ELISA.

Apoptotic MNC-secretomes in experimental stroke

2 Data Files

<http://dx.doi.org/10.6084/m9.figshare.1051645>

Discussion

For over a decade, MSCs have been known to have beneficial effects on the outcome of several disease entities (Assmus *et al.*, 2011; Chen *et al.*, 2001; Crigler *et al.*, 2006; Lagasse *et al.*, 2000). In our previous studies we were able to show that apoptotic MNC-secretomes share some of the regenerative characteristics of stem cells and, based on the data presented in this work, considerably more. We show here that apoptotic MNC-secretomes derived from both rats (rMNC^{apo sec}) and humans (hMNC^{apo sec}) caused a reduction of lesion volumes in rats subjected to MCAO. Neurological evaluations revealed an improvement in motor and sensory function, which was not observed in the control group. Furthermore, apoptotic MNC-secretomes derived from humans (hMNC^{apo sec}) (i) activate several mechanisms ultimately leading to the expression of protective proteins in cultured primary human glial cells, such as astrocytes, Schwann cells and human neurons, and (ii) induce notable sprouting of neurites in primary neuron cultures. Additionally, hMNC^{apo sec} contain BDNF and lead to increased presence of BDNF in plasma of rats treated with hMNC^{apo sec}. Neurotrophic factors and proteins involved in protective pathways seem to be triggering the therapeutic factors found in our experiments.

Crigler and coworkers described the ability of MSCs to express neuro-regulatory molecules and to promote neuronal cell survival (Crigler *et al.*, 2006). In the literature, MSCs are described to home to injured areas and regenerate damaged tissue by either causing cytoprotection, anti-inflammation or by inducing activation of endogenous stem cells (Gnecchi *et al.*, 2012; Siegel *et al.*, 2012;

Williams & Hare, 2011). Recently, it became commonly accepted that possible stem cell effects are derived from the paracrine factors secreted by MSCs (Di Santo *et al.*, 2009; Jayaraman *et al.*, 2013). This theory of paracrine factors aiding in regenerative processes emerges as a possible explanation for the therapeutic potential of apoptotic MNC-secretomes shown previously in myocardial infarction and, given our new data, in ischemic stroke (Ankersmit *et al.*, 2009; Lichtenauer *et al.*, 2011a; Lichtenauer *et al.*, 2011b). The mechanisms of action seem to be a matter of immunomodulation and cytoprotection (Ankersmit *et al.*, 2009; Lichtenauer *et al.*, 2011a; Lichtenauer *et al.*, 2011b). Cultured glial cells incubated with apoptotic MNC-secretomes revealed an upregulation of several proteins involved in conveying cytoprotective signals, such as CREB, HSP27, Erk 1/2, and Akt. These results suggest that apoptotic MNC-secretomes affect different pathways within the ischemic cascade, and most prominently they appear to act via anti-apoptotic pathways. In concert with this it is tempting to speculate that the enhanced cell survival of glial cells is beneficial for neurons since glial cells are known to support and protect neurons (Ferrer *et al.*, 2001). In rats subjected to MCAO the overexpression of HSP27 resulted in a 30% reduction of infarct sizes (van der Weerd *et al.*, 2010). The extracellular signal-regulated kinases Erk 1/2, part of the MAPK-families (mitogen activated protein kinase), are thought to play a role in cell survival and proliferation (Roux & Blenis, 2004). Furthermore, activation of the prosurvival kinase Akt reduces the proapoptotic signaling that is triggered by ischemia. It is suggested that Akt activation protects against ischemic brain injury by suppressing the proapoptotic JNK3 (c-Jun N-terminal kinase-3) pathway (Zhang *et al.*, 2007). The activation of the transcription factor CREB induces BDNF, which plays an important role in neuronal protection (Ferrer *et al.*, 2001). Studying the brain's ischemic cascade, where repair processes are initiated through the expression of several of these aforementioned survival proteins, an upregulation of protective proteins and pathways by a targeted treatment is obviously a welcome effect (Moskowitz, 2010).

Our data on CREB phosphorylation and neurite sprouting also suggest direct positive effects of apoptotic MNC-secretomes on neurons. We show here that apoptotic MNC-secretomes contain BDNF and enhance systemic, most likely indirect, BDNF secretion in rats after injection with human apoptotic MNC-secretomes. Neurotrophic factors may play a critical role in the treatment of cerebral ischemia (Abe, 2000). It was discussed in the literature that BDNF is among the most important neurotrophic factors due to its capability to promote neurogenesis and angiogenesis, to prevent neuronal cell death, and to modulate local inflammatory processes (Jiang *et al.*, 2011; Ploughman *et al.*, 2009; Schäbitz *et al.*, 2007). In light of these data it seems arguable that apoptotic MNC-secretomes provide, at least in part, indirect protection in this experimental stroke model via BDNF. When we integrate all these recent findings into our suggested mode of action of apoptotic MNC-secretomes in ischemic stroke, we can, step by step, characterize it as a biological, battling the ischemic cascade on several fronts. As mentioned before, the overall mechanism of action of our compound could be linked to the release of paracrine factors (Korf-Klingebiel *et al.*, 2008).

We decided to run two experimental settings in order to investigate (i) whether syngeneic rMNC^{apo sec} are able to attenuate ischemic lesion volumes and (ii) to further define whether xenogenic hMNC^{apo sec}, produced according to GMP criteria and virus-inactivated, are equally potent as rMNC^{apo sec}. This extended two-step experimental approach was chosen because hMNC^{apo sec} are very close to the final product that is intended for later clinical use. hMNC^{apo sec} can be produced effectively and securely using whole blood, similar to blood products such as packed red cells. Also, allogeneic apoptotic MNC-secretomes derived from multiple healthy donors could be pooled and lyophilized. In the future, the proposed ability of hMNC^{apo sec} to reduce ischemic injury in the early phases of stroke may even imply its use in combination with established therapeutic concepts such as arterial recanalization. Considering that inflammatory processes are particularly aggressive in ischemia associated with reperfusion, the suppression of inflammation provided by hMNC^{apo sec} would be a fitting addition to reperfusion therapy (Stowe *et al.*, 2009). Experiments investigating the anti-inflammatory action of apoptotic MNC-secretomes in our setting of experimental MCAO are subject to future studies. We agree that rat and human apoptotic MNC-secretomes are hardly comparable, representing a limitation of this study. In this preclinical setting of stroke, however, we were able to find similar effects through both. The intention of this study was to investigate whether there is any beneficial effect of MNC-secretomes in this preclinical setting of stroke. To avoid possible loss of potency in the xenogenic setting (hMNC^{apo sec} in rat MCAO), we decided to use treatment twice instead of only once in the allogeneic experiments (rMNC^{apo sec} in rat MCAO). This approach further allowed us to reduce the required amount of animals according to the principle of the three R's (replacement, reduction and refinement)

(Richard, 2001). This small study with all its agreeable limitations was done to see if the promising data obtained from previous studies might be translatable into experimental ischemic stroke. We realize that larger animal studies with a more thorough observation according to STAIR criteria are needed to further uncover effects of hMNC^{apo sec} in experimental stroke and also to set a time window at which this treatment is feasible (Fisher *et al.*, 2009).

Conclusion

We suggest that apoptotic MNC-secretomes have multifaceted, direct and indirect, neuroprotective characteristics acting through different ways in the ischemic cascade (inflammation, apoptosis, ischemia). Rats treated with apoptotic MNC-secretomes in this experimental stroke study expressed smaller lesion volumes than control animals and showed improvement in neurological function over time. Based on our findings, we believe that apoptotic MNC-secretomes derived from human blood can aid in the development of new treatment strategies in ischemic stroke.

Data availability

figshare: Apoptotic MNC-secretomes in experimental stroke. doi: 10.6084/m9.figshare.1051645 (Altmann *et al.*, 2014).

Author contributions

Study design: PA, HJA, TH, CG *In vivo* studies: PA, TH, DT *In vitro* studies: MM, PA, DT, LB, BG Statistical analyses: RR Manuscript: PA, HJA, FL.

Competing interests

The Medical University of Vienna has claimed financial interest (Patent number: PCT/EP09/67534, filed 18 Dec 2008; Patent name: Pharmaceutical preparation comprising supernatant of blood mononuclear cell). Hendrik Jan Ankersmit is a shareholder of APO-SCIENCE AG, which owns the rights to commercialize apoptotic MNC-secretomes for therapeutic use. All other authors declare that they have no competing interests. APOSCIENCE AG is a funder of his study.

Grant information

This study was funded by the Christian Doppler Laboratory for cardiac and thoracic diagnosis and regeneration.

Acknowledgements

The authors would like to thank Simon Fleissner, Stefan Janik, Mohammad Kasiri, Andreas Mitterbauer and everyone at the Department of Biomedical Research, Medical University of Vienna, for their kind support and assistance.

References

- Abe K: **Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury.** *J Cereb Blood Flow Metab.* 2000; 20(10): 1393–1408. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ankersmit HJ, Hoetzenecker K, Dietl W, *et al.*: **Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium.** *Eur J Clin Invest.* 2009; 39(6): 445–456. [PubMed Abstract](#) | [Publisher Full Text](#)

- Altmann P, Mildner M, Haider T, *et al.*: **Apoptotic MNC-secretomes in experimental stroke.** *figshare.* 2014. [Data Source](#)

- Assmus B, Iwasaki M, Schächinger V, *et al.*: **Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow.** *Eur Heart J.* 2011; 33(15): 1911–9. [PubMed Abstract](#) | [Publisher Full Text](#)

- Bederson JB, Pitts LH, Germano SM, *et al.*: **Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats.** *Stroke*. 1986; 17(6): 1304–1308.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brunner S, Engelmann MG, Franz WM: **Stem cell mobilisation for myocardial repair.** *Expert Opin Biol Ther*. 2008; 8(11): 1675–1690.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chen J, Li Y, Wang L, *et al.*: **Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats.** *Stroke*. 2001; 32(4): 1005–1011.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Crigler L, Robey RC, Asawachaicharn A, *et al.*: **Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neurogenesis.** *Exp Neurol*. 2006; 198(1): 54–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Di Santo S, Yang Z, Wyler von Ballmoos M, *et al.*: **Novel cell-free strategy for therapeutic angiogenesis: *in vitro* generated conditioned medium can replace progenitor cell transplantation.** *PLoS One*. 2009; 4(5): e5643.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fadok VA, Bratton DL, Henson PM, *et al.*: **Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences.** *J Clin Invest*. 2001; 108(7): 957–962.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ferrer I, Krupinski J, Goutan E, *et al.*: **Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat.** *Acta Neuropathol*. 2001; 101(3): 229–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fisher M, Feuerstein G, Howells DW, *et al.*: **Update of the stroke therapy academic industry roundtable preclinical recommendations.** *Stroke*. 2009; 40(1): 2244–2250.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fonarow GC, Smith EE, Saver JL, *et al.*: **Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.** *Circulation*. 2011; 123(7): 750–758.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gauvin G, Nims R: **Gamma-irradiation of serum for the inactivation of adventitious contaminants.** *PDA J Pharm Sci Technol*. 2010; 64(5): 432–435.
[PubMed Abstract](#)
- Giaume C, Koulakoff A, Roux L, *et al.*: **Astroglial networks: a step further in neuroglial and gliovascular interactions.** *Nat Rev Neurosci*. 2010; 11(2): 87–99.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gnecchi M, Danieli P, Cervio E: **Mesenchymal stem cell therapy for heart disease.** *Vascul Pharmacol*. 2012; 57(1): 48–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hoetzenecker K, Assinger A, Lichtenauer M, *et al.*: **Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfusion acute myocardial infarction model: role of platelet aggregation and vasodilation.** *Basic Res Cardiol*. 2012; 107(5): 1–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hoetzenecker K, Zimmermann M, Hoetzenecker W, *et al.*: **Mononuclear cell secretome protects from experimental autoimmune myocarditis.** *Eur Heart J*. 2013.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Iadecola C, Anrather J: **Stroke research at a crossroad: asking the brain for directions.** *Nat Neurosci*. 2011; 14(11): 1363–1368.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jayaraman P, Nathan P, Vasanthan P, *et al.*: **Stem cells conditioned medium: a new approach to skin wound healing management.** *Cell Biol Int*. 2013; 37(10): 1122–1128.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jensen BC, Patterson C: **Heart factory or fiction?: cardiac progenitor cells and regeneration.** *Circulation*. 2013; 128(20): 2181–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jiang Y, Wei N, Lu T, *et al.*: **Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats.** *Neuroscience*. 2011; 172: 398–405.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Joyce N, Annett G, Wirthlin L, *et al.*: **Mesenchymal stem cells for the treatment of neurodegenerative disease.** *Regen Med*. 2010; 5(6): 933–946.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Korf-Klingebiel M, Kempf T, Sauer T, *et al.*: **Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction.** *Eur Heart J*. 2008; 29(23): 2851–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lagasse E, Connors H, Al-Dhalimy M, *et al.*: **Purified hematopoietic stem cells can differentiate into hepatocytes *in vivo*.** *Nat Med*. 2000; 6(11): 1229–1234.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lambrecht B, Mohr H, Knüver-Hopf J, *et al.*: **Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.** *Vox Sang*. 1991; 60(4): 207–213.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lemmens R, Steinberg GK: **Stem cell therapy for acute cerebral injury: what do we know and what will the future bring?** *Curr Opin Neurol*. 2013; 26(6): 617–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lichtenauer M, Mildner M, Baumgartner A, *et al.*: **Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarction.** *Basic Res Cardiol*. 2011a; 106(4): 645–655.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lichtenauer M, Mildner M, Hoetzenecker K, *et al.*: **Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study.** *Basic Res Cardiol*. 2011b; 106(6): 1283–1297.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Longa EZ, Weinstein PR, Carlson S, *et al.*: **Reversible middle cerebral artery occlusion without craniectomy in rats.** *Stroke*. 1989; 20(1): 84–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mildner M, Hacker S, Haider T, *et al.*: **Secretome of peripheral blood mononuclear cells enhances wound healing.** *PLoS One*. 2013; 8(3): e60103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Moskowitz MA: **Brain protection: maybe yes maybe no.** *Stroke*. 2010; 41(10 Suppl): S85–S86.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nedelmann M, Wilhelm-Schwenkmezger T, Alessandri B, *et al.*: **Cerebral embolic ischemia in rats: correlation of stroke severity and functional deficit as important outcome parameter.** *Brain Res*. 2007; 1130(1): 188–196.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nims RW, Gauvin G, Plavsic M: **Gamma irradiation of animal sera for inactivation of viruses and mollicutes—a review.** *Biologicals*. 2011; 39(6): 370–377.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nold-Petry CA, Rudloff I, Baumer Y, *et al.*: **IL-32 promotes angiogenesis.** *J Immunol*. 2010; 15(2): 589–602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ploughman M, Windle V, MacLellan CL, *et al.*: **Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats.** *Stroke*. 2009; 40(4): 1490–1495.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Qi D, Liu H, Niu J, *et al.*: **Heat shock protein 72 inhibits c-Jun N-terminal kinase 3 signaling pathway via Akt1 during cerebral ischemia.** *J Neurol Sci*. 2012; 317(1–2): 123–129.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Richard S: **Animal research: the need for a middle ground, Let's promote the three Rs of animal research: replacement, reduction, and refinement.** *BMJ*. 2001; 322(7281): 248–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Roger VL, Go AS, Lloyd-Jones DM, *et al.*: **Executive summary: heart disease and stroke statistics—2012 Update: a report from the American Heart Association.** *Circulation*. 2012; 125(1): 188–197.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Roux PP, Blenis J: **ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.** *Microbiol Mol Biol Rev*. 2004; 68(2): 320–344.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Saas P, Gaugler B, Perruche S: **Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome.** *Ann N Y Acad Sci*. 2010; 1209: 118–126.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schäbitz WR, Steigleder T, Cooper-Kuhn CM, *et al.*: **Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis.** *Stroke*. 2007; 38(7): 2165–2172.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Siegel G, Krause P, Wöhrle S, *et al.*: **Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential.** *Stem Cells Dev*. 2012; 21(13): 2457–2470.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stowe AM, Adair-Kirk TL, Gonzales ER, *et al.*: **Neutrophil elastase and neurovascular injury following focal stroke and reperfusion.** *Neurobiol Dis*. 2009; 35(1): 82–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Strong K, Mathers C, Bonita R: **Preventing stroke: saving lives around the world.** *Lancet Neurol*. 2007; 6(2): 182–187.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Swanson RA, Morton MT, Tsao-Wu G, *et al.*: **A semiautomated method for measuring brain infarct volume.** *J Cereb Blood Flow Metab*. 1990; 10(2): 290–293
[PubMed Abstract](#) | [Publisher Full Text](#)
- Thum T, Bauersachs J, Poole-Wilson PA, *et al.*: **The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle.** *J Am Coll Cardiol*. 2005; 46(10): 1799–1802.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Truelsen T, Piechowski-Józwiak B, Bonita R, *et al.*: **Stroke incidence and prevalence in Europe: a review of available data.** *Eur J Neurol*. 2006; 13(6): 581–598.
[PubMed Abstract](#) | [Publisher Full Text](#)
- van der Weerd L, Tariq Akbar M, Aron Badin R, *et al.*: **Overexpression of heat shock protein 27 reduces cortical damage after cerebral ischemia.** *J Cereb*

Blood Flow Metab. 2010; **30**(4): 849–856.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Wallis C, Melnick JL: **Photodynamic inactivation of animal viruses: a review.** *Photochem Photobiol.* 1965; **4**(2): 159–170.

[PubMed Abstract](#) | [Publisher Full Text](#)

Williams AR, Hare JM: **Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.** *Circ Res.* 2011; **109**(8): 923–940.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Wilson BE, Mochon E, Boxer LM: **Induction of bcl-2 expression by**

phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. *Mol Cell Biol.* 1996; **16**(10): 5546–5556.

[PubMed Abstract](#) | [Free Full Text](#)

Wollert K, Drexler H: **Cell therapy for the treatment of coronary heart disease: a critical appraisal.** *Nat Rev Cardiol.* 2010; **7**(4): 204–215.

[PubMed Abstract](#) | [Publisher Full Text](#)

Zhang Y, Park TS, Gidday JM: **Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation.** *Am J Physiol Heart Circ Physiol.* 2007; **292**(6): H2573–81.

[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status: ? ✓ ?

Version 2

Reviewer Report 03 November 2014

<https://doi.org/10.5256/f1000research.5935.r6549>

© 2014 Boltze J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Johannes Boltze

Department of Cell Therapies, Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany

I want to thank the authors for their thorough amendments made on their paper. While not every single response is absolutely convincing (at least to me), the overall quality of the paper is clearly above average.

Importantly, all study limitations are well discussed or are expected to be implemented in the next revision. Hence, the paper can be considered a good starting point for further investigations and clearly deserves a broad audience.

Point 1:

Physiological parameters to be assessed may also comprise non-invasively recordable items such as heart rate, core body temperature etc. If using the filament model as one of the more invasive approaches, blood samples can also be easily collected for basic blood chemistry including pH. The state-of-the-art of filament models also includes CBF monitoring (e.g. by Laser Doppler) during ischemia induction.

The animal well-being argument is not completely convincing while the missing information are a relevant drawback of the paper and neglecting such information may easily induce a bias.

However, such bias is at least partially compensated by randomization and this is the only severe flaw in my mind. Hence, thorough discussion of these limitations is sufficient given the ample high-quality information provided by the paper.

Randomization strategy: my comment was rather directed towards the randomization method (e.g. throwing a coin, random generator etc.), but this is a minor point. A clear statement on randomization and blinding strategies is fine. Thanks for adding this.

Point 2:

Still a flaw, but OK for early exploratory research. The rationales provided in the response should be integrated in the manuscript to their full extent.

Point 3 to 5:

No additional comments.

Point 6:

In figure 1 it still reads "0,7" instead of 0.7.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 30 October 2014

<https://doi.org/10.5256/f1000research.5935.r6551>

© 2014 Chopp M et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Michael Chopp

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA

Hongqi Xin

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA

The authors have addressed my concerns appropriately in the revised version.

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 13 August 2014

<https://doi.org/10.5256/f1000research.4517.r5562>

© 2014 Zhou A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An Zhou

Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA, USA

In this work, the authors examined the therapeutic potential of secretory proteomes of apoptotic mononuclear cells (MNC^{apo sec}) in treating focal ischemic stroke, modeled on rats with permanent MCAO. They found that intraperitoneal administration of MNC^{apo sec} prepared from either rat splenocytes or human circulating blood could significantly reduce MCAO-induced brain infarct. The authors also attempted to identify protein factors in the MNC^{apo sec} that may play a role in the observed neuroprotection, and suggested BDNF. Further, in an *in vitro* setting, the authors analyzed changes in levels of a number of proteins known to mediate anti-apoptotic responses or neuronal regeneration in three different types of cell cultures, namely astrocytes, Schwann cells and neurons, upon treating the cultures with MNC^{apo sec}. An increase in some of selected proteins led to the suggestion of activation of several cytoprotective signaling cascades.

The topic of the work is of significance in developing feasible therapeutics for stroke. The same group has previously published on the use of MNC^{apo sec} in treating myocardial infarction. Thus the current findings are supportive of the potential of MNC^{apo sec}. Concerns exist, however, on several issues:

1. Lack of description of irradiation-treated MNC, especially in the splenocyte-derived cultures. Though referred to as apoptotic MNC, no experimental data were shown to demonstrate the induction and the extent of irradiation-induced apoptosis, for the period during which the conditioned media were collected. Do the two cell cultures (rat splenocytes-derived and human PBMC-derived) respond to irradiation with comparable characteristics? Are their secretomes comparable?
2. Please provide evidence on whether proteins in the intraperitoneally administered MNC^{apo sec} may have reached the brain region of MCAO territory. This information would be instrumental in helping to understand the mechanisms that underlie the action of MNC^{apo sec}.
3. Post-MCAO neurological examinations were conducted at 6, 24 and 48 hours. The covered period was short in regard to the development of infarction and neurological impairments.
4. For the MNC^{apo sec}, please provide protein quantities administered. Different cell cultures or the same culture under different conditions, even with identical cell numbers, may differ in secretion rates.
5. The rationale for using three different cultures *in vitro* to investigate the cellular response upon MNC^{apo sec} application is somewhat unconvincing. Astrocytes, Schwann cells and neurons may react to MNC^{apo sec} administration differently in brain *in vivo*. Why not perform immunohistochemical analyses of proteins of interests on brain sections?

6. The determination of plasma BDNF levels included only 3 animals per data point. Was there a power determination to justify this small sample size?
7. Wording: in the title, the abstract and manuscript text, there appeared a somewhat interchangeable use of “ameliorate neurological damage”, “regenerative potential” and “promote neuronal cell survival”. Please revise to be more accurate and concise.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 25 July 2014

<https://doi.org/10.5256/f1000research.4517.r5568>

© 2014 Chopp M et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Michael Chopp

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA

Hongqi Xin

Department of Neurology, Henry Ford Hospital, Detroit, MI, USA

The authors in this report examined the regenerative potential of conditioned medium derived from rat and human apoptotic mononuclear cells (MNC) in experimental stroke. They found that administration of rat as well as human apoptotic MNC-secretomes (rMNC^{apo sec} and hMNC^{apo sec}) significantly reduced ischemic lesion volumes and improved neurological function after stroke in both treatment groups. Furthermore, co-incubation of human astrocytes, Schwann cells and neurons with hMNC-secretomes resulted in activation of several signaling cascades associated with the regulation of cytoprotective gene products and enhanced neuronal sprouting in vitro. These data indicate that apoptotic MNC-secretomes elicit neuroprotective effects on rats that have undergone ischemic stroke. Overall, this is an interesting study. However; there are some important pieces of information missing that should be addressed to improve the manuscript:

1. The authors should include the references for their protocol on inducing apoptotic rat MNCs, as well as the references for the protocol on rat MNC preparation. Data need be presented showing apoptosis and characterizing of their rat MNCs.
2. The authors mentioned in the Materials and Methods that they will discuss the rationale for the two-step-approach of their hMNC^{apo sec} administration. However, this rationale is absent from the text. It is important to address why the authors employed two dosages instead of one dose (like the rMNC^{apo sec}).

3. In the part “*Neuronal sprouting assay*”, the authors should describe with more precision the methods they employed for measurement of neurite length.
4. In the part “*Determination of BDNF in rat plasma*”, the authors should include the dose and amount of hMNC^{apo sec} they administered to rats.
5. In the Results “*Apoptotic MNC-secretomes induce CREB phosphorylation and neuronal sprouting in human primary neurons and contain BDNF*”, the authors state that “*Interestingly, only high amounts of BDNF (356,6±13,66 pg/mL) were detected in hMNC^{apo sec}, suggesting an exclusive role for this neurotrophic factor in hMNC^{apo sec} (Figure 7).*” But these data are not shown in Figure 7.
6. The authors used a comma symbol as decimal point, and the number of significant figures should be uniform throughout the manuscript.
7. Typos in the text, e.g. “rays” in third line of the conclusion part should be “ways”.

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 15 Oct 2014

Patrick Altmann, Medical University of Vienna, Vienna, Austria

Thank you for your helpful report. Your suggestions have allowed us to make our manuscript better and present our data more accurately.

1. *The authors should include the references for their protocol on inducing apoptotic rat MNCs, as well as the references for the protocol on rat MNC preparation. Data need be presented showing apoptosis and characterizing of their rat MNCs.*

Thank you for this suggestion. We conducted an additional experiment which allowed us to compare apoptosis rates of irradiated and non-irradiated MNCs using Annexin/PI staining and flow cytometry (please see “new” Figure 1). For our active compound, we found that 85% of rat MNCs that had been irradiated and cultured for 18 hours were apoptotic.

Also, we referenced the piece of work where we generated and utilized rat apoptotic MNC-secretomes for the first time.

2. *The authors mentioned in the Materials and Methods that they will discuss the rationale for the two-step-approach of their hMNC^{apo sec} administration. However, this rationale is absent from the text. It is important to address why the authors employed two dosages instead of one dose (like the rMNC^{apo sec}).*

Thank you for letting us know that this explanation has gotten lost somehow. Since we already had the most experience with apoptotic MNC-secretomes administered 40 minutes after myocardial infarction we decided to start our stroke research at this time window as well. This first investigation was mostly intended to show the potential of apoptotic MNC-secretomes in stroke rather than setting a particular time window for our treatment or being able to tell the best dosage for its application. We are aware of the limitations of this study design and we agree that additional experiments need to be done in order to see how the administration of apoptotic MNC-secretomes at different or, for that matter, later time points affect outcome after ischemic stroke.

We applied the “human” dose twice in order to see if there was an additional benefit for the doubled dose. We agree, though, that rat and human apoptotic MNC-secretomes are hardly comparable, representing a limitation of this study. To avoid possible loss of potency in the xenogenic setting (human MNC-secretomes in rat MCAO) we decided to use treatment twice compared to only once in the allogeneic experiments (rat MNC-secretomes in rat MCAO). This approach further allowed us to reduce the required amount of animals according to the principle of the three R's (replacement, reduction and refinement)¹.

3. *In the part “Neuronal sprouting assay”, the authors should describe with more precision the methods they employed for measurement of neurite length.*

Thank you for your comment. A blinded observer set a random area of the photographed cell culture (as seen in Figure 7b) using Adobe Photoshop software (i) of cells treated with human apoptotic MNC-secretomes and (ii) of cells treated with cell culture medium (control). The areas in each photograph measured 1420x2456 pixels. Subsequently, they picked and marked visible distinct, full-length and non-overlapping 30-35 neurites using ImageJ software. Another blinded investigator measured the lengths of these marked neurites using ImageJ software. We added this more detailed explanation to the Materials and Methods section.

4. *In the part “Determination of BDNF in rat plasma”, the authors should include the dose and amount of hMNC^{apo sec} they administered to rats.*

Thank you for making us aware of this. We added this to the manuscript. As in all studies here, we used secretomes of 12.5 million apoptotic MNCs.

5. *In the Results “Apoptotic MNC-secretomes induce CREB phosphorylation and neuronal sprouting in human primary neurons and contain BDNF”, the authors state that “Interestingly, only high amounts of BDNF (356,6±13,66 pg/mL) were detected in hMNC^{apo sec}, suggesting an exclusive role for this neurotrophic factor in hMNC^{apo sec} (Figure 7).” But these data are not shown in Figure 7.*

Thank you for showing this confusion. You can see that we now added a new panel to this Figure (now “new” Figure 8) with panel (a) showing how we only traced BDNF in

our compounds and panel (b) showing BDNF levels of rats treated with our compounds.

6. *The authors used a comma symbol as decimal point, and the number of significant figures should be uniform throughout the manuscript.*

Thank you for mentioning this. We replaced all commas by decimal points throughout the manuscript. Also, the number of significant figures are now uniform throughout the manuscript in order to increase readability.

7. *Typos in the text, e.g. "rays" in third line of the conclusion part should be "ways".*

Thank you. We proof-read the manuscript a couple more times.

References

1. Smith R: Animal research: the need for a middle ground. *BMJ*. 2001; **322** (7281): 248-249
[PubMed Abstract](#) | [Free Full Text](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

Reviewer Report 21 July 2014

<https://doi.org/10.5256/f1000research.4517.r5480>

© 2014 Boltze J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Johannes Boltze

Department of Cell Therapies, Fraunhofer-Institut für Zelltherapie und Immunologie IZI, Leipzig, Germany

The article by Altmann and colleagues assesses the therapeutic impact of conditioned medium from both human and rodent apoptotic mononuclear cells (MNC). The paper reports highly interesting findings that not only contribute significantly to the understanding of adult cell-based therapies for ischemic diseases, but also shade some different light on the field.

Of particular value is the inclusion of a tailored statistical model by a professional statistician as this enhances reliability of results and their interpretation. Moreover, the method section is extensive, allowing easy reproduction of experiments by other labs. In summary, the article is

clearly above the average quality of similar studies, highly informative, and relevant.

There are, however, a number of minor weak points that may be corrected or at least require some more detailed discussion.

1. Please report all available physiological parameters of animals during MCAO and details on the randomization strategy applied.
2. Why was the treatment started in a time window of <1h after stroke onset. This is clinically irrelevant and prevents collection of post-stroke baseline function. What was the rationale for applying secretomes from rat cells just one time, but two times from human cells? Why was the injection done i.p. and not i.v. or i.a. as common in the field?
3. Behavioral data should be presented as mean +/- standard deviation. For details, please see [Carter \(2013\)](#).
4. Please explain the rationale of the surprisingly short post-stroke surveillance period of just 48 hours. Both STEPS and STAIR committees recommend at least 1 month of post-stroke observation in preclinical studies, so there should be strong argument for underscoring this significantly.
5. The discussion relies heavily on MSC which, potentially, is a bit distracting. There are ample papers discussing mechanisms of therapeutic impact by MNC, primarily from umbilical cord and bone marrow. The discussion should be directed towards those populations.
6. There are ample commas (as typical in German) in decimal numbers that should be replaced by periods.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 15 Oct 2014

Patrick Altmann, Medical University of Vienna, Vienna, Austria

Thank you for your valuable and kind comments. Having included them in our manuscript, we feel that we were able to further increase the value of our manuscript.

1. *Please report all available physiological parameters of animals during MCAO and details on the randomization strategy applied.*

We agree that physiological parameters during surgery ensure the well-being of our animals, however after careful consideration we chose to avoid additional strain on our animals (through cannulizations of blood vessels, etc.). Preparing and designing our study, we found that other studies also abstained from invasive monitoring

during surgery^{1 2 3}. To our knowledge, the model we used represents a well-established and often published procedure and therefore possesses predictable characteristics.

Regarding the randomization process, the surgeon was blinded to treatment. After surgery, the animals' tails were labeled and observers blinded to treatment and previous scores assessed neurological function. We clarified this in the manuscript (Materials and Methods).

2. *Why was the treatment started in a time window of <1h after stroke onset. This is clinically irrelevant and prevents collection of post-stroke baseline function. What was the rationale for applying secretomes from rat cells just one time, but two times from human cells? Why was the injection done i.p. and not i.v. or i.a. as common in the field?*

Thank you for mentioning this. We are aware of the time "issue" and realize that our setting might be partially out of the ordinary. Since we already had the most experience with apoptotic MNC-secretomes administered 40 minutes after myocardial infarction we decided to start our stroke research at this time window as well. This first investigation was mostly intended to show the potential of apoptotic MNC-secretomes in stroke rather than setting a particular time window for our treatment or being able to tell the best dosage for its application. We are aware of the limitations of this study design and we agree that additional experiments need to be done in order to see how the administration of apoptotic MNC-secretomes at different or, for that matter, later time points affect outcome after ischemic stroke.

We applied the "human" dose twice in order to see if there was an additional benefit for the doubled dose. We agree, though, that rat and human apoptotic MNC-secretomes are hardly comparable, representing a limitation of this study. To avoid possible loss of potency in the xenogenic setting (human MNC-secretomes in rat MCAO) we decided to use treatment twice compared to only once in the allogeneic experiments (rat MNC-secretomes in rat MCAO). This approach further allowed us to reduce the required amount of animals according to the principle of the three R's (replacement, reduction and refinement)⁴.

Concerning the injection route, we chose to administer our compounds intraperitoneally because (i) we felt it was easier to do, (ii) we had the most experience with applying medication via i.p. injections, and (iii) we considered it less invasive than intravenous application. Also, when we designed this study, we found some articles that did describe use of i.p. injections^{5 6 7}.

3. *Behavioral data should be presented as mean +/- standard deviation.*

Thank you for letting us know about this. We corrected this as requested.

4. *Please explain the rational of the surprisingly short post-stroke surveillance period of just 48 hours. Both STEPS and STAIR committees recommend at least 1 month of post-stroke observation in preclinical studies, so there should be strong argument for underscoring*

this significantly.

We absolutely agree that our small study does not meet STEPS/STAIR criteria. This very first investigation with all its agreeable limitations was done to see if the promising data obtained from previous studies in other fields of regenerative medicine might be translatable into experimental ischemic stroke. We realize that larger animal studies with a more thorough observation and surveillance in accordance with STAIR criteria are needed to further uncover effects of human apoptotic MNC-secretomes in experimental stroke. We added this information to the Discussion (second paragraph).

5. *The discussion relies heavily on MSC which, potentially, is a bit distracting. There are ample papers discussing mechanisms of therapeutic impact by MNC, primarily from umbilical cord and bone marrow. The discussion should be directed towards those populations.*

Thank you for showing this confusion. The first paragraph of the Discussion is intended to summarize what we know about MSCs and how we came to use secretomes of MNCs in our previous research and how we learned that they actually share some of the regenerative characteristics of MSCs. The second paragraph should point out how actually paracrine factors rather than stem cells themselves account for their regenerative properties and how this was observed in several studies. After that we discuss that our data indicates that neurotrophic factors involved in protective pathways seem to be triggering that therapeutic effect that we saw in our experiments. This is also mentioned in the Discussion and we included a new reference ⁸.

6. *There are ample commas (as typical in German) in decimal numbers that should be replaced by periods.*

Thank you. We replaced all ample commas in decimal numbers with periods.

References

1. Zhou L, Li F, Xu HB, Luo CX, et al.: Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. *Nat Med*.2010; **16** (12): 1439-1443 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Son HY, Han HS, Jung HW, Park YK: Panax notoginseng Attenuates the Infarct Volume in Rat Ischemic Brain and the Inflammatory Response of Microglia. *J Pharmacol Sci*.2009; **109** (3): 368-379 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Elango C, Devaraj SN: Immunomodulatory effect of Hawthorn extract in an experimental stroke model. *J Neuroinflammation*.2010; **7** (97). [PubMed Abstract](#) | [Free Full Text](#) | [Publisher Full Text](#)
4. Smith R: Animal research: the need for a middle ground. *BMJ*. 2001; **322** (7281): 248-249 [PubMed Abstract](#) | [Free Full Text](#) | [Publisher Full Text](#)
5. Ahmad AS, Yun YT, Ahmad M, Maruyama T, et al.: Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. *Neurotox Res*.2008; **14** (4): 343-351 [PubMed](#)

Abstract

6. Sahin S, Alkan T, Temel SG, Tureyen K, et al.: Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischemia in rats. *J Clin Neurosci*.2010; **17** (2): 227-231 [PubMed Abstract](#) | [Publisher Full Text](#)
7. Barakat W, Safwet N, El-Maraghy NN, Zakaria MN: Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade. *Eur J Pharmacol*.2014; **724**: 43-50 [PubMed Abstract](#) | [Publisher Full Text](#)
8. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, et al.: Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction.*Eur Heart J*.2008; **29** (23): 2851-2858 [PubMed Abstract](#) | [Publisher Full Text](#) | [Reference Source](#)

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research